7-116695774-G-C
Variant names:
Variant summary
Our verdict is Benign. The variant received -9 ACMG points: 0P and 9B. BP4_StrongBS1_SupportingBS2
The NM_000245.4(MET):c.-14-3297G>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00126 in 491,904 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as not provided (no stars).
Frequency
Genomes: 𝑓 0.0033 ( 2 hom., cov: 32)
Exomes 𝑓: 0.00033 ( 0 hom. )
Consequence
MET
NM_000245.4 intron
NM_000245.4 intron
Scores
1
12
Clinical Significance
Conservation
PhyloP100: 0.943
Publications
3 publications found
Genes affected
MET (HGNC:7029): (MET proto-oncogene, receptor tyrosine kinase) This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers. [provided by RefSeq, May 2016]
COMETT (HGNC:51196): (cytosolic oncogenic antisense to MET transcript) This gene encodes a natural antisense transcript highly expressed in papillary thyroid carcinomas harboring BRAF V600E mutation or RET gene rearrangements. This lncRNA induces the downstream MAPK pathway and is part of a co-expression network including different oncogenes belonging to the MAPK and PI3H/AKT pathways. In thyroid carcinomas, this gene has oncogenic properties associated with increased proliferation and drug resistance. [provided by RefSeq, Jan 2020]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -9 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.0037544668).
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.00332 (505/152292) while in subpopulation AFR AF = 0.011 (459/41552). AF 95% confidence interval is 0.0102. There are 2 homozygotes in GnomAd4. There are 240 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High Homozygotes in GnomAd4 at 2 AD,AR,Unknown gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MET | NM_000245.4 | c.-14-3297G>C | intron_variant | Intron 1 of 20 | ENST00000397752.8 | NP_000236.2 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00331 AC: 504AN: 152174Hom.: 2 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
504
AN:
152174
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.000542 AC: 80AN: 147618 AF XY: 0.000540 show subpopulations
GnomAD2 exomes
AF:
AC:
80
AN:
147618
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000333 AC: 113AN: 339612Hom.: 0 Cov.: 0 AF XY: 0.000280 AC XY: 53AN XY: 189500 show subpopulations
GnomAD4 exome
AF:
AC:
113
AN:
339612
Hom.:
Cov.:
0
AF XY:
AC XY:
53
AN XY:
189500
show subpopulations
African (AFR)
AF:
AC:
77
AN:
9270
American (AMR)
AF:
AC:
19
AN:
27612
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
12202
East Asian (EAS)
AF:
AC:
0
AN:
14308
South Asian (SAS)
AF:
AC:
0
AN:
59428
European-Finnish (FIN)
AF:
AC:
0
AN:
26694
Middle Eastern (MID)
AF:
AC:
2
AN:
2912
European-Non Finnish (NFE)
AF:
AC:
4
AN:
171050
Other (OTH)
AF:
AC:
11
AN:
16136
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.422
Heterozygous variant carriers
0
4
9
13
18
22
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome AF: 0.00332 AC: 505AN: 152292Hom.: 2 Cov.: 32 AF XY: 0.00322 AC XY: 240AN XY: 74474 show subpopulations
GnomAD4 genome
AF:
AC:
505
AN:
152292
Hom.:
Cov.:
32
AF XY:
AC XY:
240
AN XY:
74474
show subpopulations
African (AFR)
AF:
AC:
459
AN:
41552
American (AMR)
AF:
AC:
37
AN:
15302
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
3468
East Asian (EAS)
AF:
AC:
0
AN:
5186
South Asian (SAS)
AF:
AC:
0
AN:
4818
European-Finnish (FIN)
AF:
AC:
0
AN:
10624
Middle Eastern (MID)
AF:
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
AC:
5
AN:
68024
Other (OTH)
AF:
AC:
4
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.501
Heterozygous variant carriers
0
25
50
76
101
126
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
10
Asia WGS
AF:
AC:
3
AN:
3478
ClinVar
Significance: not provided
Submissions summary: Other:1
Revision: no classification provided
LINK: link
Submissions by phenotype
not specified Other:1
Sep 19, 2013
ITMI
Significance:not provided
Review Status:no classification provided
Collection Method:reference population
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
DANN
Benign
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T
MetaRNN
Benign
T
MetaSVM
Benign
T
PhyloP100
PROVEAN
Benign
N
REVEL
Benign
Sift
Pathogenic
D
MutPred
Gain of ubiquitination at K4 (P = 0.0121);
MVP
ClinPred
T
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.